SCHEMBL29959009

SCHEMBL29959009

Clc1cnnc(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1493464 1.00
SCHEMBL2043830 0.74
SCHEMBL13521798 0.72
SCHEMBL802302 0.72
SCHEMBL2043832 0.72
SCHEMBL802856 0.72
SCHEMBL2045262 0.72
SCHEMBL29959076 0.72
SCHEMBL13859208 0.67 MEN1 (0.47)
SCHEMBL30775657 0.67 HRH4 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115135642-B Inhibitors of EGFR mutant forms 缆图药品公司 2025-03-04 CN disclosed
EP-4433470-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME Blueprint Medicines Corporation (US) 2024-09-25 EP disclosed
CN-116159449-A Method for preparing reverse osmosis membrane and reverse osmosis membrane prepared by same 沃顿科技股份有限公司 2023-05-26 CN disclosed
WO-2023092088-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME BLUEPRINT MEDICINES CORPORATION (US) 2023-05-25 WO disclosed
WO-2023092107-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME BLUEPRINT MEDICINES CORPORATION (US) 2023-05-25 WO disclosed
CN-115135642-A Inhibitors of mutant forms of EGFR 缆图药品公司 2022-09-30 CN disclosed